A research team led by MIT scientist Daniel Anderson, the study's senior author, wanted to find a way to generate CAR-NK cells directly inside patients without removing cells, according to a report by MIT News dated October 13, 2026, because producing them outside the body poses difficulties similar to those involved in producing CAR-T cells. To do this, lipid nanoparticles carry messenger RNA into the cells, providing the blueprint for a CAR that enables the killer cell to recognize, for example, the protein CD19 on B cells or CD3 on misdirected T cells. The study's lead authors are Yuang Chen, Julia Monkovic and Haseeb Mughal, with Robert Langer listed as another author. In an aggressive form of melanoma, three of five mice treated with the nanoparticles achieved complete tumor remission.
How the nanoparticles specifically reprogram NK cells
According to the study by Chen et al. in Nature Biotechnology, the so-called NtLNPs were developed using engineered, biparatopic NK-cell ligands that specifically bind to receptors on natural killer cells, delivering the mRNA to the right cells. According to the authors, systemic administration of this CAR mRNA generates CAR-NK cells directly inside the treated animals. In mice, the leading nanoparticles were able to modify up to about 80 percent of natural killer cells, with minimal effects outside the target cells, according to the study. Against solid tumors, the researchers also used nanoparticles that target the inhibitory checkpoint NKG2A, thereby increasing the antitumor effect by reducing immunosuppression mediated by the molecule Qa-1b.

What the mouse experiments showed
In healthy mice, CAR-NK cells directed against CD19 completely eliminated all circulating B cells. In a model of autoimmune hepatitis, in which misdirected T cells attack the body's own liver, CAR-NK cells directed against CD3 destroyed almost all of these autoreactive T cells, and the liver damage healed after just one injection.
Why use NK cells instead of T cells against misdirected T cells
The researchers specifically use NK cells against diseased T cells because CAR-T cells genetically engineered to target T-cell proteins can kill one another in addition to the diseased cells they are intended to target. According to the MIT report, this problem does not occur when NK cells are used as the tool. Anderson said that if patients could receive just an infusion of nanoparticles in the future, this would greatly simplify the process and reduce costs. According to the MIT report, the research was funded in part by Sanofi, the Marble Center for Cancer Nanomedicine and a Koch Institute grant from the National Cancer Institute.

In comparison: What CAR-NK cells have achieved in patients so far
In the clinical study by Marin et al., 18 of the 37 patients treated with CAR-NK cells (48.6 percent) achieved a response with partial or complete remission on day 30, with 10 patients (27 percent) in complete remission; after one year, 68 percent of patients were alive. A systematic review published on June 13, 2025, found complete response rates for such CAR-NK cells produced outside the body ranging from 25 to 85 percent by lymphoma subtype in B-cell lymphomas, across ten studies published between 2018 and 2025 involving a total of 150 patients, although all studies were uncontrolled and only four included more than three patients. Severe side effects such as cytokine release syndrome of grade 3 or higher, immune effector cell-associated neurotoxicity or graft-versus-host disease were not reported in these studies; the authors consider the results and low rates of side effects encouraging but call for larger controlled studies. A team at Fudan University in Shanghai is also pursuing a similar in vivo approach using lipid nanoparticles against solid tumors through several types of immune cells, with prolonged survival in three mouse models. For the MIT nanoparticles, further research is needed to determine whether the technology is safe in humans, according to ScienceDaily.
What remains unresolved before moving from mice to patients
As of November 8, 2026, no CAR-NK cell therapy has received approval from the U.S. Food and Drug Administration, neither the MIT method nor other approaches, while numerous research groups are working on their development against cancer or autoimmune diseases, according to the MIT report. For the MIT method, a report by the specialist magazine The Medicine Maker adds that CAR expression peaked after about 24 hours and was barely detectable after 72 hours, meaning repeated doses could be needed, and that the researchers detected antibodies against the fragments used for targeting. According to the science portal Hayadan, it also remains unclear which tissues the nanoparticle cargo reaches, how long the effect lasts and what happens to healthy cells that carry the same target structures. According to the portal, possible cost and manufacturing advantages over removing cells for processing outside the body are also not yet clinically established, even though hundreds of doses of conventional CAR-NK cells can already be produced from a single cord blood donation.
